IRulya Therapeutics, Inc. (IRLA)
31.00
+1.69
(+5.77%)
USD |
NASDAQ |
Nov 06, 16:00
30.85
-0.15
(-0.48%)
After-Hours: 20:00
IRulya Therapeutics Research and Development Expense (Annual) : 35.38M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 35.38M |
| December 31, 2024 | 18.59M |
| December 31, 2023 | 9.247M |
| December 31, 2022 | 25.18M |
| December 31, 2021 | 60.80M |
| Date | Value |
|---|---|
| December 31, 2020 | 61.31M |
| December 31, 2019 | 30.21M |
| December 31, 2018 | 10.08M |
| December 31, 2017 | 9.099M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Korsana Biosciences, Inc. | 0.959M |
| PepGen Inc. | 69.65M |
| Q32 Bio, Inc. | 19.16M |
| Bridgebio Oncology Therapeutics, Inc. | 121.20M |
| Arrowhead Pharmaceuticals, Inc. | 585.26M |